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a b s t r a c t
Human hepatitis B virus (HBV) is the prototype of a family of small DNA viruses that productively infect
hepatocytes, the major cell of the liver, and replicate by reverse transcription of a terminally redundant
viral RNA, the pregenome. Upon infection, the circular, partially double-stranded virion DNA is converted
in the nucleus to a covalently closed circular DNA (cccDNA) that assembles into a minichromosome, the
template for viral mRNA synthesis. Infection of hepatocytes is non-cytopathic. Infection of the liver may
be either transient (o6 months) or chronic and lifelong, depending on the ability of the host immune
response to clear the infection. Chronic infections can cause immune-mediated liver damage progressing
to cirrhosis and hepatocellular carcinoma (HCC). The mechanisms of carcinogenesis are unclear. Antiviral
therapies with nucleoside analog inhibitors of viral DNA synthesis delay sequelae, but cannot cure HBV
infections due to the persistence of cccDNA in hepatocytes.
& 2015 Elsevier Inc. All rights reserved.
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1. Introduction
It has been known, since at least the 1940s, that blood and plasma
samples may contain a virus(es) that causes transient and chronic
hepatitis (MacCallum, 1947), also known as post-transfusion hepati-
tis. Moreover, a possible association with hepatocellular carcinoma
(HCC) was noted by the 1950s (Edmondson and Steiner, 1954;
Higginson et al., 1957). The unknown infectious agent was named
hepatitis B virus (HBV), to distinguish it from another infectious
agent transmitted primarily by a fecal/oral route, hepatitis A virus
(HAV) (MacCallum, 1947). HAV does not cause chronic hepatitis. The
nature of hepatitis B virus was unknown, as were means for testing
donor blood and plasma for its presence. Thus, post-transmission
hepatitis was common following transfusion, afﬂicting up to 30–40%
or more of recipients (Shimizu and Kiamoto, 1963).
This changed in the mid-1960s, when Blumberg and colleagues
discovered that a serum antigen, previously identiﬁed in their lab and
found to be common in leukemia patients treated via blood trans-
fusion, was actually the component of the infectious agent, HBV
(Blumberg, 1977; Blumberg et al., 1967). This serum antigen, known
as Australia antigen because of its identiﬁcation in an Australian
Aborigine, was found as 22 nm rods and spheres in the blood of
infected individuals. These particles were subviral and comprised of
the three HBV envelope proteins, L, S and M, now known collectively
as hepatitis B surface antigen (HBsAg) (Bayer et al., 1968; Dane et al.,
1970). The enveloped virus, 42 nm in diameter, is much less abundant
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in serum than HBsAg. Virions were named Dane particles after the
ﬁrst author of the electron microscopy study in which they were ﬁrst
visualized (Dane et al., 1970). HBV is transmissible not just among
humans but also in the great apes (Bancroft et al., 1977; Barker et al.,
1973; Linnemann et al., 1984; Warren et al., 1999; Zuckerman et al.,
1978), including the chimpanzee, which was used until recently as an
experimental model. HBV can also infect the macaque (Macaca
fascicularis)(Dupinay et al., 2013) and, in a laboratory setting, the tree
shrew (Tupaia belangeri)(Walter et al., 1996).
The ability to assay for HBsAg led to screening of blood banks
and a 2–3-fold reduction in the incidence of post-transfusion
hepatitis, after discounting cases of hepatitis following transfusion
of blood from paid blood donors (Alter et al., 1972; Senior et al.,
1974). Many of the remaining cases, including from paid donors,
were thought due to an agent referred to as NonANonB hepatitis
virus(es). A major cause of NonANonB hepatitis, hepatitis C virus
(Engle et al., 2014), was identiﬁed in 1989 (Choo et al., 1989, 1990).
The HBsAg assay also conﬁrmed the suspected association
between chronic HBV infection and HCC in humans (Beasley
et al., 1981; Blumberg et al., 1975; Prince et al., 1975). This link
has not so far been reported in great apes chronically infected with
HBV. HBsAg, puriﬁed from HBV carriers, became the ﬁrst vaccine
to prevent HBV infection (Buynak et al., 1976; Purcell and Gerin,
1975) and, consequently, HBV-associated HCC.
The studies of the molecular biology of HBV carried out by
Robinson and colleagues showed that HBV contained a double-
stranded DNA genome about 3 kbp in length, as well as an
endogenous DNA polymerase activity that could incorporate nucleo-
tides into the viral DNA genome in an in vitro reaction of virions in
which the viral envelope was disrupted with non-ionic detergent
(Kaplan et al., 1973; Robinson et al., 1974; Robinson and Greenman,
1974). Following up on this work, Summers and colleagues showed
that virion DNAwas actually a partially double-stranded DNA held in
a relaxed circular conformation by a short cohesive overlap between
the 50 ends of the two DNA strands. One strand was complete, the
other incomplete (Fig. 1), leaving a single stranded gap that could be
repaired, in vitro, by the endogenous DNA polymerase (Summers
et al., 1975). The endogenous reaction carried out in the presence of
P-32-labeled deoxynucleotides was used by Summers and others to
screen serum samples of different host species for a hepatitis B like
virus. This approach rapidly led to the discovery of HBV-like viruses
in eastern woodchucks (woodchuck hepatitis virus) (Summers et al.,
1978), domestic ducks (duck hepatitis B virus) (Mason et al., 1980),
and Beechey ground squirrels (ground squirrel hepatitis virus)
(Marion et al., 1980). Chronic infection leads to HCC in woodchucks
and ground squirrels (Marion et al., 1986; Summers et al., 1978;
Tennant and Gerin, 2001), but not in ducks. Collectively, the HBV
family of viruses is now known as the hepadnaviridae, with two
genera, orthohepadnaviruses (infecting mammals), of which HBV is
the prototype, and avihepadnavirus (infecting birds), of which DHBV
is the prototype (Fauquet et al., 2005).
Fig. 1. Genome structure, genes and mRNAs of hepatitis B virus. The relaxed-
circular DNA genome of HBV with a complete minus strand and incomplete plus
strand is shown (inner circle), along with the major mRNAs, all of which end at a
common polyadenylation signal located in the core open reading frame. Dashed
lines at the 50 end of mRNAs indicate the use of staggered starts sites for preCore/
core and M/S, as described in the text. All open reading frames have a clockwise
direction. The single stranded gap in the plus strand can be ﬁlled in in vitro by the
viral RT, which is covalently attached to the 50 end of minus strand DNA. In
avihepadnaviruses, the plus strand is generally complete except for DR2, which
remains as an RNA/DNA hybrid (Lien et al., 1987). DR1 and DR2 represent 11 base
direct repeats that have an important role in viral DNA synthesis. Minus strand
synthesis exhibits a short terminal redundancy created during reverse transcription
of pregenomic RNA (Fig. 2).
Fig. 2. Replication of HBV DNA. Reverse transcription begins with binding of the
pol protein to the 50 copy of a stem–loop structure epsilon (ε) located in the
terminal redundancy of pregenome RNA (A), which facilitates packaging into viral
nucleocapsids. Then, following copying of 3 nucleotides from a bulge in the side of
epsilon, the polymerase translocates to the copy of the 11 nt sequence, DR1, located
in the 30 terminal redundancy. The basis for the translocation is unclear but is
sufﬁcient to align the nts copied from epsilon with a complementary sequence in
DR1. Reverse transcription then continues to the 50 end of the pregenome (B, C),
with the template being degraded by an RNase H encoded within the pol protein.
The terminal 18 nts including the CAP and DR1 are not degraded. Normally this
oligonucleotide translocates to DR2, where it can anneal because of the identity of
DR1 and DR2 (D). Plus strand synthesis then initiates and extends to the 50 end of
the minus strand. Circularization then occurs, facilitated by the short terminal
redundancy on the minus strand (E). Plus strand synthesis stops before completed
(F), perhaps because nucleocapsids containing incomplete plus strands are pack-
aged into viral envelopes, preventing access to dNTPs. For avihepadnaviruses, the
plus strand is generally complete except for DR2. About 10% of the time, the RNA
primer of plus strand synthesis fails to translocate, resulting in in situ priming to
produce double stranded linear DNA (dsl DNA) (G). Both rcDNA and dslDNA can be
converted to cccDNA when transferred to the nucleus, though the pathways are
different and, for dsl DNA, generally lead to defective cccDNA. Dsl DNA is a
preferred substrate for integration into host DNA.
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Animal models, in particular the duck and woodchuck, were
essential for early investigations on viral replication and for testing
of antiviral drugs. With the help of the duck model, Summers,
Mason and Taylor discovered that hepadnaviruses replicate via
reverse transcription (Mason et al., 1982; Summers and Mason,
1982) in a pathway similar to that of retroviruses, except that
hepadnavirus DNA is converted into a minichromosome, cova-
lently closed circular DNA (cccDNA) (Fig. 2), that is the template
for synthesis of the viral RNAs (Bock et al., 2001; Newbold et al.,
1995). The woodchuck and duck also provided systems to inves-
tigate the course of transient and chronic infections and the
inﬂuence of nucleoside-based antiviral therapies. Moreover, the
models provided an important source for primary hepatocyte
cultures, the only cell culture-based systems permissive for
hepadnavirus infections until the early 2000s (Gripon et al.,
2002). Starting in the mid 1980s, functional analyses of viral
genomes using recombinant DNA technology and testing of
reverse transcriptase (RT) inhibitors for antiviral therapies became
easier with the identiﬁcation of liver tumor cell lines that
supported HBV replication from transfected DNA (Condreay
et al., 1990; Sells et al., 1987; Shih et al., 1989; Sureau et al.,
1986; Tsurimoto et al., 1987; Yaginuma et al., 1987).
Early studies in ducks and woodchucks, as well as chimpan-
zees, had indicated that transient hepadnavirus infections could be
cleared even after infection of apparently the entire hepatocyte
population (Barker et al., 1973; Berquist et al., 1973; Hoofnagle
et al., 1978; Jilbert et al., 1992; Kajino et al., 1994; Ponzetto et al.,
1984). This was surprising, since no mechanism was known that
would clear viral DNA from the nucleus of hepatocytes, which
constitute a self-renewing population with a very low turnover
rate. Thus, it seemed a priori that cccDNA elimination would
require killing of all infected hepatocytes, leading to liver failure
and death, whereas most patients recover uneventfully. Histologic
analyses did not support the notion that hepatocytes were being
replaced by proliferation and differentiation of liver stem/progeni-
tor cells. This led to the idea that there must be non-cytopathic
mechanism(s) helping, along with hepatocyte killing, to eliminate
cccDNA and cure transient infections, and that these might
eventually be exploited as therapy for chronic infections.
To look for mechanisms of HBV clearance that were not solely
dependent on the death of infected hepatocytes, Chisari and
colleagues carried out experiments with HBV transgenic mice
during the 1990s. These studies showed that HBV DNA replication
intermediates (Fig. 3) could be non-cytolytically cleared from
the cytoplasm of hepatocytes in response to certain cytokines
(e.g., interferon γ, TNFα) (Guidotti et al., 1996; Guidotti and Chisari,
1996). However, the mechanism of cccDNA clearance from the
nucleus remained mute, as their mice did not make cccDNA.
Studies in primary, non-dividing, duck hepatocyte cultures
infected with DHBV failed to detect a cytokine driven clearance
of cccDNA (Schultz and Chisari, 1999; Schultz et al., 1999).
Thus, further efforts to understand recovery from transient
infections in chimpanzees and woodchucks were carried out
(Mason et al., 2009b; Murray et al., 2005; Summers et al., 2003;
Wieland et al., 2004b, 2005). These studies had two principle
questions: (1) Are any hepatocytes actually cured during recovery
from HBV infection? (2) If so, how is this achieved? While there is
now strong evidence from these studies for hepatocyte curing (as
well as abundant killing), the mechanism for cccDNA elimination
remains elusive. These questions, as well as studies of chronic
Fig. 3. HBV replication cycle. The ﬁgure shows a model for the lifecycle of hepadnaviruses, as described in the text. Envelope proteins are shown in yellow, DNA-containing
capsids in blue and RNA-containing capsids in red. Upon infection mediated by the entry receptor, NTCP, virus nucleocapsids are transported to the nucleus, where rcDNA is
converted to cccDNA. cccDNA does not undergo semiconservative DNA synthesis (Tuttleman et al., 1986a). Early in infection, when envelope protein concentrations are low,
newly made nucleocapsids, with their enclosed viral DNA, are transported to the nucleus to amplify cccDNA copy number to up to 50 per hepatocyte (Tuttleman et al.,
1986b). At the same time, envelope proteins enter the ER and assemble into subviral particles (SVP) or transfer to MVBs where virion assembly is believed to occur. When
sufﬁcient envelope is present, nucleocapsids are directed to their secretory pathway and cccDNA ampliﬁcation ceases. Mature virions might exit cells through exosomes (for
details and references see the text). Virus with dsl DNA can also infect hepatocytes. cccDNA is formed from dsl DNA by non-homologous recombination, resulting in a loss of
sequences and, generally, rendering this cccDNA unable to support virus replication (Yang and Summers, 1995). Dsl DNA may also integrate into host DNA via non-
homologous recombination; this pathway does not appear to have a role in the virus life cycle. The ﬁgure does not show “empty” HBV virions produced by infected
hepatocytes because the pathway for their assembly and secretion is not yet known (Ning et al., 2011).
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infection discussed later, need to be understood ﬁrst of all in the
context of the current view of hepatocyte replacement, which was
until recently thought to include, at least under conditions of
extreme stress to the liver, stem/progenitor cell differentiation.
Under normal conditions, the hepatocyte population is self-renew-
ing, with most hepatocyte able to divide to maintain liver mass. The
hepatocyte turnover rate is uncertain. The PCNA labeling index of
S-phase hepatocytes in normal liver is about 0.05% (Mancini et al.,
1994); however, the daily turnover may be higher, depending on the
duration of S-phase in these cells. When hepatocyte proliferation is
inhibited, such as by exposure to a toxic chemical (e.g., 2-acetylamino-
ﬂuorene), presumptive hepatocyte progenitor cells (sometimes called
facultative stem cells) are observed to proliferate (Fig. 4) (Evarts et al.,
1987; Hsia et al., 1992). These cells are thought to be associated with
bile ductules in the liver, or with the associated Canals of Hering,
which form a bridge between bile ductules and the plates of
hepatocytes in which bile is formed (Fig. 4). Their proliferation seeds
the hepatic lobule, especially near the portal tracts, with ovoid cells
(oval cells) that have been thought to then differentiate into
hepatocytes. However, recent studies question the role for such a
distinct hepatocyte progenitor cell population in hepatocyte regen-
eration. In particular, hepatocyte replacement during injuries histori-
cally attributed to hepatocyte progenitor cell proliferation, in rats,
could not be replicated in mice using various means to trace cell
lineages (Schaub et al., 2014; Yanger et al., 2014). It remains unclear if
this ﬁnding is speciﬁc to mice, or also extends to rats, from which
most data on progenitor cell populations during liver injury had
historically been derived (Grompe, 2014); recent data support the
possibility they are similar (Marongiu et al., 2014). In view of these
recent data, it is not clear if hepatocyte progenitor cells exist in
humans, or play a role in hepatocyte replacement in the face of the
excessive long-term destruction of mature hepatocytes as seen in
chronic hepatitis B (Hoare et al., 2010; Kordes and Haussinger, 2013;
Riehle et al., 2011). Serial transplant studies in mice with mouse and
with human hepatocytes suggest that both young cells, as well as
mature hepatocytes with markers of senescence, are able to prolif-
erate in vivo to restore liver mass (Wang et al., 2014). That is, that
senescence is reversible. To make the picture more complicated,
recent data suggest that oval cells can form directly from mature
hepatocytes (metaplasia), proliferate, and re-differentiate to mature
hepatocytes. That is, so-called progenitor cells (oval cells), seen when
the hepatocyte population is stressed, are ﬁrst formed from mature
hepatocytes (Tarlow et al., 2014).
Based on these recent data, as well as historic observations, we
take the view here that hepatocyte replacement during both
transient and chronic infections is accomplished by proliferation
of existing hepatocytes, which may include an intermediate step of
progenitor/oval cell formation. One implication of this, discussed
below, is that HCC ultimately arises from hepatocytes, not from a
stem cell precursor originating in the bile ducts and/or Canals of
Hering. However, recent ﬁndings leave open the possibility that
HCC may arise from mature hepatocytes via pathways that include
progenitor cell formation.
Finally, like many retroviruses, mammalian hepadnaviruses
sometimes cause cancer in association with activation of host
oncogenes resulting from nearby insertion of viral DNA (reviewed
in Buendia and Neuveut, in press). Integration of hepadnavirus DNA
into chromosomes occurs by illegitimate recombination, predomi-
nately of double stranded linear (dsl) DNA, which constitutes about
10% of virion DNA and is formed as an aberrant by-product of the
Fig. 4. Liver structure. A highly idealized 2D representation of a portion of a 3D liver lobule is shown representing some of the major cell types that are present. Blood enters
through the portal vein and hepatic artery and exits at the central vein, after ﬂowing through sinusoids in which hepatocytes are separated from blood via a fenestrated
epithelium though which virus can pass. Bile produced by hepatocytes is released into bile canaliculi formed by the apical interfaces of hepatocytes and ﬂows to the bile
ducts via the Canals of Hering. Bile eventually ﬂows to larger ducts before leaving the liver. Historically, progenitor cells residing in bile ducts and/or the Canals of Hering
were thought to emerge under conditions of stress as ovoid cells (oval cells) and to differentiate into small transitional hepatocytes and ﬁnally mature hepatocytes (paths
shown as dashed lines), as well as to contribute to formation of foci of altered hepatocytes, some of which appear to be preneoplastic. Recent studies questioned the role of
oval cells in hepatocyte replacement, suggesting instead that hepatocytes themselves are able to evolve and repopulate the liver even under extreme stress to the normal
hepatocyte population. And, by inference, to give rise to foci of altered hepatocytes and HCC. A possible resolution of some of these divergent observations is suggested by
the very recent report that mature hepatocytes themselves give rise to oval cells that have the capacity to re-differentiate to hepatocytes (Tarlow et al., 2014). Thus, at
present, some of the illustrated pathways are still uncertain (indicated with ? mark). (Figure adapted from Seeger et al. (2013).)
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process normally leading to rcDNA (Fig. 2G). Integration is not
orchestrated by viral proteins (Bill and Summers, 2004; Gong et al.,
1995, 1999; Yang and Summers, 1995, 1999). However, it is still not
clear how important insertional activation of oncogenes is in most
HCCs occurring in HBV patients, and whether hepadnavirus pro-
teins expressed from integrated DNA have a direct role in initiation
or maintenance of cancer cells.
2. Molecular biology of hepadnavirus replication
Infection of hepatocytes is productive and, for the most part,
non-cytopathic. Duck hepatitis B virus, an avihepadnavirus, has
been documented to infect, in addition, bile duct epithelium of the
liver, rare exocrine cells and alpha and beta islets of the pancreas,
proximal tubular epithelium of the kidney, and possibly a subset of
splenic cells (Guo et al., 2005; Halpern et al., 1983, 1984; Jilbert
et al., 1987). In contrast to DHBV, the evidence that the orthohe-
padnaviruses infect cells other than hepatocytes has been con-
troversial, and it has not always been clear that reported infections
distinguish passive association of virus with a cell population from
its actual infection, as conventionally deﬁned by the presence of
cccDNA, the viral transcriptional template.
The life cycle of hepadnaviruses resembles that of most retro-
viruses with the distinction that genome conversion to DNA occurs
prior to the releases of virus particles (Figs. 2 and 3). Hence,
hepadnaviruses are classiﬁed as DNA viruses. HBV itself encodes
7 proteins, preCore, core, pol, X (HBx), and the three envelope
proteins, L, M, and S, which form a carboxy-terminal nested set,
S being the smallest, M the next largest, and L the largest. The extra
domains in M and L are named PreS2 and PreS1, respectively
(Fig. 1). Core is the subunit of the viral nucleocapsid and pol encodes
the enzymes needed for synthesis of viral DNA (reverse transcriptase,
RNaseH, and primer), which takes place in nucleocapsids localized to
the cytoplasm of infected hepatocytes. HBx is required for efﬁcient
transcription of cccDNA; it is not known to be a virus structural
protein. preCore is the core protein with an N-terminal signal peptide
and is proteolytically processed at its N and C termini before secretion
from infected cells, as the so-called hepatitis B e-antigen (HBeAg). Its
role in the virus life cycle is uncertain, but thought to inhibit or delay
antiviral immunity in some way. The organization of the genes on the
viral genome, or more particularly on the pregenome (the template for
reverse transcription) is somewhat reminiscent of retroviruses (Fig. 1),
but differs in at least two important ways. First, all the viral proteins
have their own mRNA except for core and pol, which share an mRNA,
the pregenome (Fig. 1). No polyproteins are produced. Second, with
the exception of the secretory protein, preCore, none of the viral
proteins are subject to post-translational proteolytic processing; in
addition, hepadnaviruses do not encode a proteinase.
Hallmarks of hepadnaviruses, hepatotropism and species speciﬁ-
city are controlled on at least two levels: virus entry and transcrip-
tion of viral RNAs. The discovery of hepatitis delta virus (HDV), a
viroid-like satellite virus of HBV, provided an excellent model system
for investigations of the viral determinants required for entry of HBV,
because HDV depends on HBV envelope proteins for infection (Taylor,
2006). However, once in the cell, HDV replicates with much higher
efﬁciency than HBV. Reverse genetic experiments with HDV led to
the identiﬁcation of a 75 aa-long domain in the N-terminus of the
preS1 domain of the large envelope protein (L) (Fig. 1) that was
required for infection of primary human hepatocytes (PHH) and of
differentiated HepaRG cells, a hepatocarcinoma-derived cell line that
is propagated in an undifferentiated form, but induced to differenti-
ate by changing cell culture conditions (Blanchet and Sureau, 2007;
Gripon et al., 2002). Experiments with DHBV infected ducklings
showed that N-myristylation of L was essential for infectivity, but not
virus assembly, an observation subsequently conﬁrmed with HBV
(Gripon et al., 1995; Macrae et al., 1991). Lipopeptides derived from
the ﬁrst 48 aa of preS1 can bind to hepatocytes permissive for HDV
and HBV infections and inhibit infection (Gripon et al., 2005).
Building on this information, Li and colleagues (Yan et al., 2012)
used the myristylated preS1-derived peptide to isolate receptor
candidates expressed in primary hepatocytes cultures derived from
tree shrews, which can be infected with HBV and HDV. They
identiﬁed the bile acid transporter, sodium taurocholate cotransport-
ing polypeptide (NTCP) and demonstrated that it is the bona ﬁde
HBV/HDV receptor. NTCP is expressed on the basolateral membrane
of hepatocytes, which is exposed to the space of Disse and separated
from the blood stream by a fenestrated endothelium. Following
ectopic expression, NTCP confers susceptibility to HBV and HDV
infections of hepatoma cell lines that are otherwise resistant to these
agents. Besides determining hepatotropism, preS1 binding to NTCP
also controls species speciﬁcity (Ni et al., 2014; Yan et al., 2013;
Zhong et al., 2013), consistent with observations of PreS function
made earlier with avihepadnaviruses (Ishikawa and Ganem, 1995).
While HDV can infect mouse cells expressing human NTCP, HBV
cannot, indicating that other factors must play a role in determining
species speciﬁcity of HBV (Ni et al., 2014; Yan et al., 2013). Uncoating,
migration of virus nucleocapsids to the nuclear membrane and
conversion of rc to cccDNA (Fig. 3) are the steps subsequent to viral
entry that might depend on host speciﬁc factors. As noted earlier,
cccDNA cannot be detected in transgenic mice expressing HBV in
hepatocytes from a transgene, also pointing to species-speciﬁc
determinants that play a role in the HBV lifecycle subsequent to
viral entry.
The mechanisms for disassembly of nucleocapsids and cccDNA
synthesis are not well understood. Puriﬁed HBV nucleocapsids
added to digitonin-permeabilized hepatoma cells accumulate in
nuclear baskets in a process that depends on the transport factors
importin alpha and beta (Rabe et al., 2003, 2009). RcDNA is released
into the cell nucleus and subsequently repaired to yield cccDNA
(Fig. 3). However, the nature of the cellular enzymes that execute the
DNA repair reaction remains elusive. A cellular polymerase and/or
the RT are required to extend the gap in plus stand DNA (Fig. 1).
Nucleoside analogues that inhibit the RT cannot prevent cccDNA
formation of DHBV, underscoring the requirement for cellular factors
in its formation (Fourel et al., 1994b). Cellular endonucleases are
required to remove a short terminally redundant sequence in rcDNA
minus strands created during viral DNA synthesis and to remove the
RT and the RNA primer on minus and plus strand DNA, respectively
(Figs. 1 and 2). Finally, a ligation reaction is required to close the gaps
in both DNA strands. This model implies that rcDNA is the direct
precursor of cccDNA. An alternative model (not shown) predicts that
a polymerase extends the 30 ends of both DNA strands and, through
DNA strand displacement synthesis, creates a double-stranded linear
DNA with a large terminal redundancy (LTR) spanning the cohesive
overlap region in rcDNA (Yang et al., 1996). Homologous recom-
bination between the LTRs would then lead to cccDNA formation
without the requirement of an endonuclease to process the ends of
rcDNA. Defective cccDNAs have been detected that could have been
created by non-homologous recombination between the LTRs of
such dsl DNAs (Yang and Summers, 1995). So far, however, dsl DNA
intermediates with these terminal redundancies have not been
detected, suggesting that they are either a very short-lived inter-
mediate or that cccDNA is formed directly from rcDNA.
CccDNA is detected in the liver within the ﬁrst day of infection of
ducklings with DHBV (Tagawa et al., 1986). CccDNA binds to histones
and forms a mini-chromosome (Bock et al., 2001; Newbold et al.,
1995). For HBV, cccDNA serves as the template for transcription of six
viral RNAs from four separate promoters, core, PreS, S and X. The
mRNAs are termed precore/core, preS, M/S and X in orthohepadna-
viruses, with preCore/core and M/S transcription directed by the core
and S promoters, respectively. The extra mRNAs result from the use
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of staggered initiation sites immediately upstream and downstream
of an AUG that is in frame with a downstream AUG directing
translation of core and S proteins. Two enhancers exhibiting binding
sites for liver speciﬁc transcription factors, including HNF4 and HNF3,
are required for the activity of the promoters and represent addi-
tional determinants for the marked hepatotropism of hepadnaviruses
(reviewed in Kosovsky et al., 1998; Moolla et al., 2002).
HBx is also required for transcription from cccDNA in HepaRG
cells and most likely in HepG2 cells infected with HBV (Lucifora
et al., 2011; Seeger and Sohn, 2014). However, the exact mechanism
of HBx action is still obscure. Evidence for direct binding of X to the
mini-chromosome has been obtained with chromatin immuno-
precipitation experiments (Belloni et al., 2009). However, the best-
documented interaction of X is with DNA damage-binding protein 1
(DDB1) and the cullin4A-RING DDB1-ubiquitin ligase (Becker et al.,
1998; Li et al., 2010). This scenario is reminiscent of Cullin4A-DDB1
binding of the V protein of paramyxoviruses, which leads to the
ubiquitination and degradation of Stat1 and hence, inhibition of the
IFN response (Leupin et al., 2003). While the interaction of HBx
with DDB1 has been ﬁrmly established with biochemical, genetic
and structural studies, the search for the HBx binding partner
targeted for ubiquitination and degradation has not yet provided
ﬁrm answers. If the Cullin4A-DDB1-HBx complex is indeed con-
trolling transcription from cccDNA, it might play a role in the
regulation of acetylation of histones, to activate transcription,
because it has been observed that in the absence of HBx, histones
of the mini-chromosome are hypoacetylated (Belloni et al., 2009).
However, these observations have to be interpreted with some
caution, because they were derived with a mimic of cccDNA derived
from transfected plasmid DNA. Nevertheless, the current hypothesis
about a role of HBx in transcription of cccDNA is exciting and
consistent with the fact that this protein is required for natural
infections of woodchucks by WHV (Zhang et al., 2001) and, by
inference, for infection by the other orthohepadnaviruses. Interest-
ingly, many avihepadnaviruses do not encode an X gene; for those
that do, the protein may not be necessary for infection of their host
(Meier et al., 2003). All known avihepadnaviruses express a larger
core protein than orthohepadnaviruses; this larger core protein
might exert an activity similar to X of HBV and WHV (Feitelson and
Miller, 1988).
The six unspliced mRNAs transcribed from HBV cccDNA encode
the seven proteins described above (for a more detailed description,
see Seeger et al., 2013). (Spliced mRNAs have been reported but their
functional signiﬁcance is still uncertain (e.g., Obert et al., 1996;
Soussan et al., 2003.) They are transported to ribosomes through a
transport mechanism that depends, at least in part, on a posttran-
scriptional cis-acting regulatory element, termed PRE, overlapping
the N-terminal portion of HBx (Huang and Liang, 1993; Huang and
Yen, 1994). Core and polymerase (RT) proteins are transcribed from
pgRNA, the latter by internal initiation. Pre-core (e-antigen) is
transcribed from a pre-core RNA, which is colinear with pgRNA,
except for a short extension at the 50 end permitting translation from
the pre-core AUG. Similarly, the middle (M) and small (S) envelope
(surface) proteins are derived from colinear mRNAs, termed preS2
and M/S, respectively, with distinct 50ends bracketing the AUG codon
of M. Large envelope (surface) protein and HBx are translated from
PreS1 and X transcripts, respectively. HBx might be produced
immediately after formation of the cccDNA mini-chromosome
resulting in activation of the other three promoters by direct or
indirect mechanism as explained above. In infected liver tissue, the
HBx transcript accumulates to much lower levels compared with the
other viral mRNAs, and often cannot be detected at all, explaining the
lack of consistent evidence of HBx expression in infected hepatocytes.
Translation of core and polymerase proteins is regulated to
account for the stoichiometric imbalance required for morphogen-
esis of icosahedral particles consisting of 240 subunits of core and
one molecule of polymerase bound to pgRNA. (The reader is referred
to recent reviews for a detailed description of the mechanism for
protein priming and reverse transcription (Hu and Seeger, in press;
Seeger et al., 2013).) Binding of the polymerase to the copy of the
stem–loop structure termed epsilon, in the 50 terminal redundancy
of the pgRNA (Fig. 2), triggers packaging and hence, the transition of
the core/pol mRNA to pgRNA for DNA replication (Bartenschlager
and Schaller, 1992; Hirsch et al., 1991). This binding reaction, which
can be reproduced in vitro, requires heat shock proteins believed to
stabilize a conformation of the polymerase for binding to the epsilon
structure (Hu and Seeger, 1996; Hu et al., 1997; Wang and Seeger,
1992). Once bound to RNA, the polymerase primes reverse tran-
scription from a tyrosine residue in the N-terminal domain of the
polymerase, termed the terminal protein (TP) domain (Weber et al.,
1994; Zoulim and Seeger, 1994). A major gap in knowledge con-
cerning DNA replication is the lack of complete structural informa-
tion about the polymerase, and in particular its TP domain, which
does not share any apparent similarities with known proteins.
Finally, in DHBV-infected ducks the majority of expressed polymer-
ase appears to accumulate in cytoplasmic lipid-containing structures
(Yao et al., 2000). However, a function for non-encapsidated poly-
merase remains obscure, although, sporadically, studies suggesting a
role in inhibiting innate immunity have been reported (Foster et al.,
1991; Wang and Ryu, 2010).
The ﬁnal product of DNA replication in cytoplasmic nucleocap-
sids is the partially double stranded rcDNA still attached to the RT at
the 50 end of minus strand DNA and attached to an RNA oligomer
derived from the 50 end of pgRNA at the 50 end of plus strand DNA
(Figs. 1 and 2). The latter fulﬁlls a role in the priming of plus strand
DNA synthesis (Lien et al., 1986; Seeger et al., 1986; Will et al., 1987).
An intricate aspect of the hepadnavirus life cycle is the fact that DNA,
but not RNA containing nucleocapsids, can assemble with envelope
proteins residing in ER membranes. Yet the signals responsible for
this transition are not known. Biochemical studies revealed differ-
ences in the phosphorylation of core proteins isolated from RNA and
DNA containing particles, respectively. DNA containing particles are
hypo-phosphorylated in a region near the C-terminus of the core
protein that contains several serine residues (Perlman et al., 2005).
While the observed reduction in phosphate might compensate for
the net increase of phosphate, a consequence of DNA synthesis, it
could also create the binding sites for envelope proteins by changing
a conformation of the C-terminal region. Unfortunately, structural
information about the C-terminal domain of nucleocapsids is not yet
available to explain distinct properties of nucleocapsids in assembly
(Crowther et al., 1994; Watts et al., 2002).
The fate of DNA containing nucleocapsids depends on the stage
of the infection of a hepatocyte. Early, when the concentration of
envelope proteins is low, nucleocapsids enter a retrograde trans-
port and deliver their DNA cargo into the cell nucleus leading
to ampliﬁcation of cccDNA copy number (Fig. 3) (Summers et al.,
1990). Later in the infection, nucleocapsids bind to envelope
proteins and mature into infections virions that are secreted into
the blood stream.
Investigations on the assembly of HBV have been hampered by
the low amount of virus produced in an infected cell, which has
been estimated as 1–10 virions per cell per day (Nowak et al.,
1996). Because envelope proteins accumulate in the endoplasmic
reticulum–Golgi intermediate compartment, a model has been
proposed where DNA-containing capsids bind to envelope pro-
teins at the ER, translocate into the lumen and exit the cells via the
secretory pathway. Hence, virion formation and secretion would
follow the pathway for assembly and secretion of the much more
abundant subviral spherical and ﬁlamentous particles (SVP) con-
sisting predominantly of M and S, and to a lesser part L envelope
proteins and lipids. However, subsequent biochemical studies
revealed that virions might use a different pathway that depends
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on proteins normally associated with the endosomal sorting complex
required for transport (ESCRT) and with the formation of multi-
vesicular bodies (MVPs) (Piper and Katzmann, 2007; Watanabe et al.,
2007). The MVB machinery is also used for budding by other
enveloped viruses including HIV (Sundquist and Krausslich, 2012).
Evidence for MVB function in HBV assembly and budding is largely
derived from DNA co-transfection studies with HBV DNA and
plasmids expressing dominant negative mutants of proteins known
to be associated with the MVB machinery such as Vsp4 and AIP1
(Kian Chua et al., 2006; Watanabe et al., 2007). A caveat with these
experiments is that the dominant negative mutants could disturb
cellular homeostasis and hence, make interpretation of the data
difﬁcult. For example, overexpression of wild-type Vsp4 causes
reduced accumulation of intracellular and extracelluar forms HBV
DNA (Kian Chua et al., 2006), while expression of dominant negative
Vsp4 increases the release of “naked” nucleocapsids from transfected
cells (Watanabe et al., 2007). Assuming that MVBs play the predicted
role in virion maturation and budding, there are several gaps in
knowledge that need to be ﬁlled to complete our understanding of
HBV assembly and release. For example, what are the signals that
direct HBV into the ESCRT pathway? Where in the infected hepato-
cyte does budding occur?
Whatever the site and exact mechanism for virus assembly
might be, a critical event during morphogenesis of virus particles
is the novel conformational arrangements of the N-terminal pre-
S1 domain of L, the large envelope protein (Bruss, 2007; Bruss
et al., 1994; Guo and Pugh, 1997; Ostapchuk et al., 1994), such that
about half of the PreS1 domains are on the cytoplasmic side and
half on the cisternal side of the membrane as virions form via
budding. The PreS1 located on the cytosolic side is required for
binding to viral nucleocapsids. The pre-S1, which had translocated
across the viral membrane, is exposed on the surface of infectious
virus particles where it functions as binding sites for NTCP, the
viral receptor, as described above. Finally, it should be noted that
so-called “empty” virus particles accumulate in sera of HBV
infected patients (Ning et al., 2011; Luckenbaugh et al., 2015. The
pathway for their assembly and the conformation of pre-S1 in
these particles is not yet known.
3. Biology of transient infections
Infection of hepatocytes appears to be non-cytopathic and
histopathology a consequence of the adaptive immune reaction to
infection, in particular, the production of virus-speciﬁc cytotoxic
T cells (CTLs). Transient infections are generally less than 6 months
in duration. Events occurring during transient infections of humans
are mostly inferred from studies of woodchucks and chimpanzees.
Virus appears to spread in the ﬁrst several weeks post-exposure
without producing more than a transient activation of the innate
immune response, lasting a few days (Guy et al., 2008; Wieland
et al., 2004a), or any apparent induction of virus neutralizing
antibodies or antiviral-CTLs (Wieland et al., 2004b). During this
phase, virus spreads through the entire hepatocyte population. This
may be followed by several weeks of productive infection, with no
evidence of inﬂammation or other overt liver damage (Kajino et al.,
1994; Summers et al., 2003; Wieland et al., 2004b). A priori, an
antiviral-CTL response arising at this stage of infection might be
expected to destroy the entire liver, leading to death of the host.
However, such an outcome, termed fulminant hepatitis, is rare.
Instead, activation of the CTL response and the associated inﬂam-
mation kills some, perhaps a majority of hepatocytes over a period
of a few weeks, but the remainder survive, are cured of their
infection, and repopulate the liver, as shown by hepatocyte lineage
tracking using viral DNA randomly integrated into host DNA during
the infection (Summers et al., 2003). Resolution of infection often
occurs without overt symptoms. A small fraction of hepatocytes
may remain infected, as evidenced by short-term follow-up studies
in ducks and woodchucks and deduced from long-term studies in
humans (Reaiche et al., 2010; Rehermann et al., 1996; Summers
et al., 2003). In these cells, replication appears to be suppressed by
the immune response, but has been observed to rebound in some
patients when the immune system is compromised (Hoofnagle,
2009); for example during chemotherapy of cancer patients.
Antiviral cytokines appear to play a major role in recovery, but
surprisingly, neutralizing antibodies do not appear to be required
(Kajino et al., 1994; Ponzetto et al., 1984; Wieland et al., 2004b).
A direct function of cytokines is to induce elimination of virus
replication intermediates from the cytoplasm of infected hepato-
cytes by mechanisms that are not well understood, although it has
been demonstrated that in DHBV infected duck hepatocyte cul-
tures, and HBV transgenic mice, IFNα interferes with packaging of
pregenomic RNA into capsids (Guo et al., 2003; Schultz et al., 1999;
Wieland et al., 2005). Clearance of cccDNA, which deﬁnes the
infected state, appears to be delayed compared to clearance of
DNA replicative intermediates (RI) in cytoplasmic nucleocapsids
(Wieland et al., 2004b). Computer modeling studies and hepato-
cyte lineage studies using randomly integrated viral DNAs as cell
markers led to the deduction that at least some cccDNA may be
cleared non-cytolytically (Mason et al., 2009b; Murray et al.,
2005); i.e., in a process dependent neither on hepatocyte death
nor compensatory division. As noted, early studies showed that
cccDNA was not reduced by interferon alpha or gamma treatment
of primary duck hepatocyte cultures infected by DHBV (Schultz
and Chisari, 1999; Schultz et al., 1999), which appears to ﬁt with
the observation that cccDNA is not lost at the time of clearance of
the cytoplasmic viral DNA (RI DNA) present in nucleocapsids
(Fig. 3) (Wieland et al., 2004b). A more recent cell culture study
presented evidence that interferon alpha, gamma and other
cytokines can induce APOBEC3, which then targets cccDNA for
depurination and degradation, and might explain non-cytolytic
clearance (Lucifora et al., 2014). This study remains controversial,
however, as depurination appeared speciﬁc to the minus strand of
cccDNA. Editing of the minus strand of HBV DNA replication
intermediates is already well-described (e.g., Noguchi et al.,
2005; Rosler et al., 2005; Suspene et al., 2005), raising the
possibility that the editing observed in cccDNA actually occurred
in the cccDNA precursor, RI DNA (Figs. 2 and 3). In brief, while
there is a basis from cell culture and in vivo studies to further
investigate non-cytolytic mechanisms for cccDNA clearance,
acquiring convincing experimental data so far remains elusive.
One alternative model, not requiring non-cytolytic loss of cccDNA,
stipulates that cccDNA is stable in infected hepatocytes and can only
be lost by cell death. Thus, curing of a hepatocyte lineage would
require elimination of RI DNA by cytokine-mediated processes,
followed by one or more rounds of mitosis to dilute out cccDNA
and produce virus-free progeny. Another model is that cccDNA is lost
when a cell divides, so hepatocyte division produces two progeny
free daughter cells (Mason and Litwin, 2002). Current in vivo data
may be consistent with a role for the latter mechanism, which
necessitates killing of about 70% of hepatocytes (based on a model,
which assumes hepatocytes divide at random to maintain liver
mass), or with this together with non-cytopathic mechanisms for
elimination of cccDNA during recovery from transient infections
(Mason et al., 2009b; Summers et al., 2003). The data do not support
a model in which cccDNA survives cell division during immune
clearance of the virus and is lost solely via cell death (Mason et al.,
2009b). Further experiments, perhaps following up on the idea that
APOBEC3 targets cccDNA, may help resolve the role of cytokines
versus cell division in cccDNA elimination.
The possibility that cccDNA can survive mitosis, at least in some
situations, was based on estimates of hepatocyte turnover during
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antiviral therapy of chronically infected woodchucks with a
nucleoside analog inhibitor of WHV DNA replication. In particular,
there was an initial cccDNA decline, consistent with estimates of
hepatocyte turnover. However, an equivalent decline in the frac-
tion of infected hepatocytes was not observed early in treatment,
suggesting that hepatocytes containing multiple copies of cccDNA
were eventually cured by diluting out cccDNA through multiple
rounds of cell division (Zhu et al., 2001). CccDNA survival through
cell division was also inferred from a study of infected hepatocytes
induced to divide in the presence of an antiviral nucleoside analog
(Dandri et al., 2000). Relevant to this latter study, cccDNA appears
stable in non-dividing primary hepatocyte cultures in which viral
DNA synthesis is blocked by nucleoside analogs (Moraleda et al.,
1997; Zhu et al., 2001). These results may suggest that cccDNA
loss during recovery from transient infections, to the extent that it
is mediated by mitosis, is dependent on cytokine effects that
destabilize cccDNA during mitosis. However, interpretation of
these antiviral-studies depends on the assumption that the anti-
viral nucleosides completely inhibited new RI DNA synthesis, and
thus cccDNA synthesis throughout the cell cycle. This assumption
has recently been called into question based on antiviral studies
with DHBV infected ducklings in which hepatocytes were prolif-
erating at a predictable rate (Reaiche-Miller et al., 2013). In brief,
as with determining if cytokines mediate cccDNA loss in non-
dividing hepatocytes, the fate of cccDNA in cycling cells also
remains elusive.
4. Chronic infections
As with transient infections, most chronic infections are thought
to begin with spread of virus through the entire hepatocyte
population. However, the immune response is ineffective and the
virus is not cleared. Approximately 90% of human HBV infections at
less than 1 year of age become chronic compared to only 5% in
adults. Most chronic infections occur at birth, from infected mothers,
or during the ﬁrst year of life. A similar inverse relationship between
age and frequency of chronic infectionwas found using the duck and
woodchuck models (Cote et al., 1991; Jilbert et al., 1998). Passive
immunization and/or vaccination of newborns at risk for perinatal
infection reduces the risk of chronic infection 410-fold (Chen et al.,
2011) and represents a major advance in reducing the worldwide
burden of chronic hepatitis B, estimated at 300–400 million.
Unfortunately, this regimen is less effective when virus titers were
high in maternal blood (Wen et al., 2013).
Although chronic infections may clear spontaneously, most are
life-long. At least early, chronic infection is associated with
persistently high virus titers, of the order of 109–1010 per ml of
serum. In humans, virus titers often decline with age, especially
after 30 years, sometimes dropping to less than 102–3 per ml
(Chen and Yang, 2011). This decline has not been documented in
ducks or woodchucks.
An idealized view of chronic HBV infection, for individuals
infected early in life, was published about 10 years ago by Yim and
Lok (2006), and is summarized in Fig. 5. In brief, once established,
chronic infection is characterized by an immune tolerant phase,
which may last up to 30 years or more. The concept of immune
tolerance is based on high virus titers (e.g., the order of 109–1010
per ml), the absence of persistently elevated alanine aminotrans-
ferase (ALT) levels in the blood stream, indicative of hepatocyte
killing and, where liver biopsies are available, the absence of
inﬂammation and/or ﬁbrosis (Lok and McMahon, 2007, 2009).
However, recent immunological studies have called into question
the concept of immune tolerance as well as the conclusion that
liver injury, albeit low level, is not ongoing in these patients
(Bertoletti and Kennedy, 2014; Kennedy et al., 1995). In any case,
patients may then enter an immune clearance phase, characterized by
one or more bouts of acute hepatitis, during each of which virus titers
may decline and afterwards rebound. Ultimately, this phase may end
with a stable reduction of virus titers to a low level, presumably
reﬂecting immune control of virus replication, possibly as seen after
resolution of transient infections. Unlike recovery from transient
infections, generally associated with anti-HBsAg IGs, HBsAg expression
may persist, perhaps from integrated DNA and residual cccDNA. Such
patients are not considered to have resolved their infections in the
sense seen after transient infections or when HBsAg disappears and is
Fig. 5. Stages of chronic HBV infection. Chronic HBV infection is thought to go through immune tolerant, immune clearance, and immune control (no disease progression)
phases. In this latter phase, the degree of ongoing liver damage can vary from none to signiﬁcant, depending on how completely virus replication is blocked (see text). HCC
incidence generally rises after the immune clearance phase, which may not be clinically apparent but can still be inferred to have occurred because of the greatly reduced
virus titers that come after it, reﬂecting immune control or restriction of virus replication. Loss of immune control may also occur after a period of disease inactivity, leading
to enhanced virus replication and exacerbation of liver damage. (Figure adapted from Yim and Lok (2006)).
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replaced by anti-HBsAg IGs. As in transient infections, symptoms may
not be severe enough, during the immune clearance phase, to lead the
patient to seek medical care. Nonetheless, the immune clearance
phase can initiate extensive damage to the liver resulting in ﬁbrosis
and cirrhosis. In a prospective study, the rate of subsequent disease
progression to cirrhosis and HCC was found to depend on virus titers
at study entry. For example, the long-term risk of HCC increased
several fold for patients with titers Z105 per ml, as compared to
patients with lower titers, suggesting some sort of ineffective balance
between immune control, virus replication, and immune killing of
hepatocytes in these patients (Chen and Yang, 2011).
Long-term infection is often associated with evolution of the virus
population, probably resulting from immune selection against viral
epitopes that lead to efﬁcient destruction of infected hepatocytes by
the antiviral immune response. One possible example is the loss of
HBeAg, either due to stop codon mutations in the signal peptide
domain or to upstream mutations in the promoter for the HBeAg
mRNA (Brunetto et al., 1999; Okamoto et al., 1994; Parekh et al.,
2003; Sato et al., 1995; Yu and Mertz, 1996). How these mutants
emerge to become a dominant virus genotype in the liver is elusive.
One possibility is that mutants that emerge have higher in vivo
replication rates than wildtype HBV and spread through the infected
liver by super-infection to become the dominant genotype. However,
work with the duck and woodchuck models does not favor this
hypothesis, as super-infection resistance seems high (Rodrigues et al.,
2014; Zhang and Summers, 1999). An alternative scenario is that
virus evolution after the liver is fully infected is largely vertical,
division of an infected hepatocyte producing two infected daughter
cells via retention of nuclear cccDNA and/or cytoplasmic RI DNA.
Thus, commonly occurring mutations might emerge because they
give the infected hepatocyte a survival advantage to escape anti-viral
CTLs (Frelin et al., 2009), allowing these cells to slowly repopulate the
liver (Mason et al., 2008). To our knowledge, the data needed to
resolve these scenarios does not yet exist. The distinction may be
important, however, because selection at the cellular level would
enhance genetic narrowing of the hepatocyte population and might
facilitate, indirectly, the clonal expansion of hepatocytes destined to
evolve to HCC (see below).
Interestingly, wild type virus re-emerges as the dominant
genotype during transmission to a new host, probably because it
has a selective advantage in spreading through the large population
of uninfected hepatocytes (51011 in adults). This selection may
be partially due to a higher replication rate, but may also be due to
an ability of wt virus to suppress the host immune response. For
instance, HBeAg, the secreted product of preCore (Fig. 1), has been
reported to suppress anti-viral immunity to core protein (Chen
et al., 2004), a capacity that is presumably transient, but adequate to
delay the process until the liver is fully infected. Thus, immune
selection seems to be a major factor, driving emergence of mutant
virus as dominant species late in an infection.
An issue related to virus evolution, but also impinging on the
question of hepatocarcinogenesis, is whether hepatocytes stably
evolve genetically or epigenetically in response to pressures placed
upon infected cells by antiviral CTLs. It has been clear since the earliest
studies of HBV infected human livers that a majority of hepatocytes
are not productively infected late in the disease (Burrell et al., 1982;
Gowans et al., 1981). This has also been observed in chronically
infected chimpanzees even in the face of persistent viremia (Mason
et al., 2009a). The vast majority of HBV negative hepatocytes in non-
cirrhotic livers of chimpanzees and of HCC patients have normal
histology (e.g., Mason et al., 2009a, 2010). Evolution of HBV-resistant
hepatocytes may be an early step in neoplastic progression, allowing
hepatocytes destined to give rise to tumors to escape elimination by
the antiviral immune response. This idea is consistent with the notion
that the hepatocyte population is entirely self-renewing.
5. Chronic hepadnavirus infection and hepatocellular
carcinoma
Many cancers, including HCC, are likely the end result of
pathologies that evolve over a lifetime (Farber and Sarma, 1987).
Studying a life-long process in chronic HBV infection is intrinsi-
cally difﬁcult, not only because of the time factor, but also because
liver biopsies are seldom taken until patients show clinical signs of
chronic liver disease (e.g., abnormally high liver enzymes in the
circulation for 6 months or more as a sign of chronic hepatocyte
destruction). Such patients are no longer in the immune tolerant
phase, and often 30 years or more in age. An unfortunate con-
sequence is that while a great deal is known about late stages of
infection, as deﬁned by signs of clinically overt disease, almost
nothing is known about evolution of liver pathology earlier in
infection. An implicit assumption in the clinical setting has been
that the immune tolerant phase is essentially apathogenic, though
recent data may challenge this perspective (Bertoletti and
Kennedy, 2014; Zoulim and Mason, 2012).
The pathogenic processes leading to HCC, as for many cancers,
are believed to involve at least three stages: initiation, promotion,
and progression (Farber and Sarma, 1987). Initiation is probably
the ﬁxation of a mutation(s) in host DNA via cell division.
Promotion would correspond to clonal expansion of mutated
hepatocytes that have an increased risk of oncogenic transforma-
tion, while progression includes the steps by which members of
these clonal populations evolve to become cancer cells. Additional
mutations would presumably occur during these latter steps.
As suggested above, emergence of a large fraction of normal-
appearing hepatocytes that are free of replicating virus may be a
step in tumor promotion, since it presumably involves clonal
expansion of virus-resistant hepatocytes. In addition, HCCs gener-
ally do not support HBV replication: for example, core protein,
which is required for replication, is detected in only about 15% of
HCCs and even in these cases, only in a minor fraction of tumor cells
(Hsu et al., 1989). This also seems to be true of preneoplastic lesions
(Govindarajan et al., 1990). Presumably related phenomena are seen
in genetic diseases of the liver that predispose to HCC such as alpha-
1-antitrypsin deﬁciency (Rudnick and Perlmutter, 2005) or in
tyrosinemia Type I, in which liver disease may be ablated due to
partial repopulation of the liver by hepatocytes in which the defect
in fumarylacetoacytase (involved in tyrosine degradation) is cor-
rected via spontaneous mutation (Demers et al., 2003; Grompe
et al., 1998; Kvittingen et al., 1994; Marongiu et al., 2008). Hence,
immune selection for hepatocytes deﬁcient in HBV replication may
be an additional basis for tumor promotion in HBV patients.
A possible basis for progression is less evident. The problem
here, as evident from recent high throughput studies of HCC
genomes, is that vast differences between tumors, and between
tumors and normal liver, obscure identiﬁcation of genetic events
that are essential, and in what order they have occurred. For
instance, does viral DNA integration near an oncogene reﬂect
initiation, promotion, or progression, and is this distinction
important for HCC development? Integration of viral DNA is a
low frequency event occurring in only 0.1–0.01% of hepatocytes
during transient infections (Summers et al., 2003). However, it is
an ongoing process and is found in 10–100% of hepatocytes by
the time HCC develops in chronic carriers. Early studies suggested
that the HBV DNA integration site in each tumor was distinct, not
even conﬁned to a single chromosome and, with a few exceptions,
not near a known oncogene (Dejean et al., 1986; Wang et al., 1990),
The apparent complexity of HCC development in humans
appeared to be in stark contrast to the scenario in woodchucks,
where early studies suggested that a much simpler picture might
eventually emerge.
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6. Evidence that integration of hepadnaviral DNA can be pro-
oncogenic
In the woodchuck model, transcriptional activation of the
N-myc2 pseudogene is found in about 80% of HCCs, often in
association with WHV integration just 50 or 30 of the ORF of the
gene, or at the distal loci b3n and win, 10 kbp and 150 kbp,
respectively, from N-myc2 (Bruni et al., 1999; Fourel et al., 1990,
1994a). The existence of additional integration sites distal to
N-myc2 that activate its transcription has also been suggested
(Bruni et al., 2006).
N-myc2 expression is common in preneoplastic foci of altered
woodchuck hepatocytes (FAH) (Yang et al., 1993), but not in
normal appearing hepatocytes. It is not known if expression in
these preneoplastic FAH is due to WHV integration. In any case,
this result suggests that N-myc2 is important in neoplastic
progression, but that additional mutations are needed to produce
an HCC. What these are remains unknown. In a small fraction
of woodchuck HCCs, proximal integration of WHV DNA along
with transcriptional activation may be found instead at N-myc1 or
C-myc (Fourel et al., 1990; Hsu et al., 1988).
To address issues related to the oncogenicity of C-myc and
N-myc2, Buendia and colleagues made transgenic mice containing
either WHV/Nmyc2 or WHV/Cmyc DNA fragments cloned from
woodchuck HCCs (Renard et al., 2000; Terradillos et al., 1997).
With WHV/C-myc, virtually all mice developed HCC by one year of
age. In the WHV/N-myc2 transgenic mice, the tumor frequency
was much lower (about 55% between 11 and 30 months of age),
perhaps due to lower transgene expression. In both transgenic
models, normal hepatocytes, preneoplastic lesions and HCCs were
found. It remains unclear if this heterogeneity reﬂects secondary
events (e.g., mutations) needed for emergence of preneoplastic
lesions and HCC (Renard et al., 2000), or heterogeneity in trans-
gene expression within the hepatocyte population, particularly in
the adult mouse in which endogenous expression of C-myc is low.
In brief, while these studies showed that myc activation is a critical
step in carcinogenesis in the woodchuck, they also re-enforced the
conclusion that HCC formation, even in this host, is a multistep
process in which most steps remain elusive.
In humans, the relationship between HBV DNA integration and
gene activation (or inactivation) and hepatocarcinogenesis are
much less clear. Genomic analyses revealed some preferences of
HBV integration near genes encoding, for example, telomerase
(TERT), the histone H3K4 methyltransferase MLL4 and cyclin E1
(CCNE1) (Sung et al., 2012). However, none of these and other
recurrent integrations have been found in more than a few percent
of HCCs, making their overall importance unclear (Ding et al.,
2012; Jiang et al., 2012; Murakami et al., 2005; Sung et al., 2012),
As alluded to above, it has not been possible to identify genes
that are uniformly activated as a direct consequence of HBV
integration.
7. Role of HBV proteins in hepatocarcinogenesis
Although most human HCCs contain integrated viral DNA,
expression of core protein has been found in only about 15% of
HCCs, and then, only in a minority of cells in the tumor (Hsu et al.,
1989). Envelope proteins are detected in about 30% of HCCs and, in
a larger fraction of tumor cells than typical of core, which might
reﬂect stringent requirement of the core promoter for hepatocyte-
speciﬁc transcription factors (Hsu et al., 1989). HBx expression has
been observed in 20–50% of HCCs (Seo et al., 1997; Su et al.,
1998) but, like core, only in a small fraction of cells in a tumor (Su
et al., 1998). Thus, there does not appear to be an obvious role for
virus proteins in maintaining the transformed state.
Evidence that HBx may, however, contribute to hepatocarcino-
genesis comes from studies with HBx transgenic mice (Koike et al.,
1994). While HBx does not increase the risk of HCC in mice with a
low spontaneous incidence, it does potentiate HCC development
when these mice are treated with DEN, a liver carcinogen, at least
in part by inhibiting DNA excision repair (Becker et al., 1998;
Madden et al., 2001; Minor and Slagle, 2014). HBx may also
promote expression of pro-carcinogenic genes in late stage liver
disease, as illustrated by faster HCC formation when the WHV/C-
myc transgenic mice described above were crossed with HBx
transgenic mice. While it seems reasonable that HBx may be
important in formation of human HCC, it remains unclear at what
stage this protein would exert its effects. It is also unclear how
expression levels in these mice compare to HBx expression in HBV
infected hepatocytes.
L protein (Fig. 1) is also speculated to have a role in hepato-
carcinogenesis. Over expression of wt L protein of HBsAg in the
liver of transgenic mice led to severe liver damage and HCC,
apparently due to a massive, persistent hepatocyte killing as a
result of excessive L mediated accumulation of HBsAg in the ER
(Chisari et al., 1989). While this massive-overexpression of L is not
a feature of HBV infection per se, it might occur late in chronic HBV
infection when some hepatocytes overexpress L giving them a
histologic appearance known as ground glass hepatocytes (Gerber
et al., 1975), perhaps for the same reason (over-expression of L in
some hepatocytes). More recently, HBsAg, particularly with muta-
tions affecting the PreS2 domain, has been suggested to contribute
to oncogenesis, possibly via induction of an ER stress response and
oxidative DNA damage due to ER accumulation of this aberrant L
protein (Pollicino et al., 2014). Ground glass hepatocytes with a
PreS2 mutant often appear in focal clusters that have been
suggested to be preneoplastic (Su et al., 2008). One of these
mutant L proteins was expressed in the hepatocytes of transgenic
mice prone to develop liver cancer. Twenty-ﬁve percent of these
mice developed HCC by 30 months of age, starting at 22 months of
age (non-transgenic sibs were not shown for comparison). In
contrast, 100% of HBx transgenic mice in the same study devel-
oped HCC between 14 and 22 months, while double transgenics
developed HCC slightly faster, at younger ages than the HBx
transgenics. In the absence of non-transgenic littermate controls,
it is not clear if the mutant L protein caused HCC; however, the
results argue that in this mouse lineage, at least, HBx is carcino-
genic and that the mutant L potentiated the effects of HBx.
In summary, there is circumstantial evidence that HBx and
possibly mutant L protein contribute to hepatocarcinogenesis. As
with insertional activation of oncogenes, it is not yet clear when or
how often, in the process of cellular transformation, these proteins
actually play a vital and direct role.
8. Antiviral therapy and HCC
In most HBV carriers, liver disease progresses through cirrhosis
to HCC, though HCC may also occur in the non-cirrhotic liver. Thus,
the goals of antiviral therapy are to halt the progression of cirrhosis,
or even lead to a reversion, and to block the appearance of HCC.
Two approaches are used, interferon therapy and treatment with
nucleoside analog inhibitors of HBV reverse transcription. Interferon
therapy aims to induce permanent immune control of infection
via stimulation of the hosts’ antiviral immune response and, not
unexpectedly, is most successful during the immune clearance
phase of the infection; i.e., in patients with signiﬁcant immune
mediated liver damage when therapy is initiated (Hoofnagle, 1990).
The main goal of nucleoside analog therapy is to block viral DNA
synthesis and thereby reduce the number of infected hepatocytes,
as cccDNA is lost via hepatocyte turnover. As with interferon
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therapy, nucleoside analog therapy may also potentiate immune
control. Combination therapy has not so far provided a major
improvement is this regard, probably because many patients
responsive to an interferon induced cure are also those responsive
to nucleoside analog mediated cure (Wong et al., 2014).
An obvious problem with nucleoside therapy in the majority of
cases, in which immune control is not achieved, is the necessity of
life-long treatment to prevent virus rebound. For this and other
reasons, antiviral therapy has not been recommended for patients
still in the immune tolerant phase of infection (Lok and McMahon,
2009). With nucleoside analogs, reasons to not treat immune
tolerant patients include potential drug toxicity, cost and, until
recently, the potential emergence of drug resistant strains of HBV.
With the more recent FDA-approved agents, Tenofovir and Ente-
cavir, the emergence of drug-resistant variants in treatment naïve
patients (no history of therapy with nucleosides with a lower
resistance threshold) is, so far, almost absent.
Following the current treatment guidelines, it has been found
that therapy reduces short-term risk (e.g., ﬁve year) of HCC several
fold (Hosaka et al., 2013). Nucleoside analog therapy can also
inhibit and sometimes reverse the progression of cirrhotic and
ﬁbrotic liver injury (Marcellin et al., 2013; Tana and Hoofnagle,
2013), which can be life threatening.
What remains unclear is whether the risk of HCC can be
reduced to background levels by starting treatment earlier, in the
immune tolerant phase (Hosaka et al., 2013). While there is
evidence that the immune tolerant phase is actually associated
with antiviral immunity targeting infected hepatocytes (Bertoletti
and Kennedy, 2014; Wang et al., 2010), it is not yet clear if this
poses an HCC risk. Indeed, it remains uncertain why HCC is not
totally prevented even following current treatment guidelines. Is
this because an HCC risk is set early, during the immune tolerant
phase, or because of the inherent difﬁculties in identifying patients
until well after they have progressed to late stages of infection
where preneoplastic lesions are already present? For this among
other reasons, a short-term curative therapy, as now available for
HCV carriers (Afdhal et al., 2014), is highly desirable, especially one
that can be applied at any stage of chronic hepatitis B including the
immune tolerant phase.
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